GBT Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Global Blood Therapeutics (GBT) PT Lowered to $67 at Cowen
February 24, 2022 6:55 AM ESTCowen analyst Ritu Baral lowered the price target on Global Blood Therapeutics (NASDAQ: GBT) to $67.00 (from $72.00) while maintaining an Outperform rating.
The analyst commented, "GBT reported Q4 Oxbryta sales of $56.1MM (+8% q/q), in line with guidance. NRxs were down... More
Global Blood Therapeutics (GBT) Misses Q4 EPS by 23c
February 23, 2022 5:06 PM ESTGlobal Blood Therapeutics (NASDAQ: GBT) reported Q4 EPS of ($1.36), $0.23 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $55.44 million.
For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.
... More